Following CDC approval to vaccinate children aged 6 months to 5 years, 4-year-old Eleanor Kahn sits with her father Alex while nurse Jillian Mercer administers the Moderna vaccine for the coronavirus disease (COVID-19) at Rady Children’s Hospital. in San Diego, California, USA, June 21, 2022.
Mike Blake | Reuters
Moderna has asked the Food and Drug Administration to approve its ommicron booster shots for children, the company announced Friday.
Moderna has filed two separate FDA authorization requests, one for adolescents ages 12 to 17 and one for children ages 6 to 11. – old, later this year.
The Centers for Disease Control and Prevention said in a paper published Tuesday they expect children to be eligible for the ommicron boosters in mid-October, pending FDA approval. The CDC’s Vaccine Advisory Committee has scheduled meetings for Oct. 19 and 20.
Pfizer told the CDC advisory committee earlier this month that it expects to ask the FDA to allow ommicron boosters for children ages 5 to 11 by early October.
US health regulators approved Moderna’s ommicron boosters for adults earlier this month. Pfizer boosters are approved for people 12 years and older.
The new shots target the omicron BA.5 sub-variant and the original Covid strain that first emerged in China in late 2019. The FDA and CDC expect the new boosters to provide superior protection against infection and disease as they target the most common ommicron sub-variant.
The old vaccines, which were designed to fight the original Covid strain, no longer provide meaningful protection against infection and mild illness because the virus has mutated so strongly. There is also concern that the effectiveness of the original shots in preventing hospitalization and serious illness is beginning to decline.
Public health officials are confident in the new ommicron BA.5 boosters, although it’s unclear how effective they will be in the real world. The recordings are authorized without human clinical trial data